Focused On-demand Library for Rho GTPase-activating protein 26

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UNA1

UPID:

RHG26_HUMAN

Alternative names:

GTPase regulator associated with focal adhesion kinase; Oligophrenin-1-like protein; Rho-type GTPase-activating protein 26

Alternative UPACC:

Q9UNA1; O75117; Q5D035; Q9BYS6; Q9BYS7; Q9UJ00

Background:

Rho GTPase-activating protein 26, also known as GTPase regulator associated with focal adhesion kinase, Oligophrenin-1-like protein, and Rho-type GTPase-activating protein 26, plays a crucial role as a GTPase-activating protein for RHOA and CDC42. These activities are pivotal for cell cycle regulation and cellular dynamics.

Therapeutic significance:

The protein's involvement in juvenile myelomonocytic leukemia, a severe pediatric disorder marked by hematopoietic stem cell compartment malignancy, highlights its potential as a therapeutic target. The discovery of a chromosomal translocation t(5;11)(q31;q23) in leukemic cells underscores the protein's critical role in disease pathogenesis.